2 active not recruiting, 2 recruiting, 1 enrolling by invitation. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Active not recruiting 2, Recruiting 2, Enrolling by invitation 1 |
| Phase 2 | 2 | Recruiting 2 |
Follow Nkarta, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) NKX019, Fludarabine, Cyclophosphamide - Systemic Sclerosis, Idiopathic Inflammatory Myopathies | Phase 1 / Phase 2 | Recruiting | Nkarta, Inc. | 240 | 2024-11-04 | 2026-10-30 |
| A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus NKX019, Cyclophosphamide LD - Systemic Lupus Erythematosus | Phase 1 | Enrolling by invitation | Hospital for Special Surgery, New York | 6 | 2024-07-01 | 2026-06-22 |
| A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) NKX019, Fludarabine, Cyclophosphamide - Lupus Nephritis, Primary Membranous Nephropathy | Phase 1 / Phase 2 | Recruiting | Nkarta, Inc. | 120 | 2024-06-13 | 2026-06-04 |
| NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers NKX019 - Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | Nkarta, Inc. | 150 | 2021-08-20 | 2026-04-20 |
| NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS NKX101 - CAR NK cell therapy - Relapsed/Refractory AML, AML, Adult | Phase 1 | Active not recruiting | Nkarta, Inc. | 61 | 2020-09-21 | 2024-12-27 |
Lupus Nephritis (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Arthritis, Rheumatoid (1) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Lupus Erythematosus, Systemic (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Myelodysplastic Syndromes (1) · Myositis (1) · Scleroderma, Diffuse (1) · Scleroderma, Systemic (1) · Waldenstrom Macroglobulinemia (1)
Cyclophosphamide (4) · fludarabine (3) · Cytarabine (1) · Decitabine (1)
United States (5) · Australia (2) · Puerto Rico (1)
David Shook, MD (2) · Anca D Askanase, MD, MPH (1)